Find A Clinical Trial

Disease Type: Pancreatic

Trial ID CG-745-2-08
Sponsor ID Crystal Genomics

A Phase 1b/2, Dose-escalation, Randomized, Multicenter Study of Maintenance Ivaltinostat plus Capecitabine or Capecitabine Monotherapy in Patients with Metastatic Pancreatic Adenocarcinoma Whose Disease Has Not Progressed on First Line FOLFIRINOX Chemotherapy

Principal Investigator
M. Adham Salkeni, MD, FRCPC
1 Location
Trial ID C-800-22
Sponsor ID Agenus

“A PHASE II RANDOMIZED, OPEN-LABEL, TRIAL OF NAB-PACLITAXEL + GEMCITABINE WITH OR WITHOUT BOTENSILIMAB (AGEN1181) IN PATIENTS WITH METASTATIC PANCREATIC CANCER WHO HAVE PROGRESSED ON PRIOR 5FU + LEUCOVORIN + IRINOTECAN + OXALIPLATIN (FOLFIRINOX)”

Principal Investigator
M. Adham Salkeni, MD, FRCPC
1 Location
Trial ID NUV868
Sponsor ID NUV-868-01

Phase 1/2 Safety and Efficacy Study of NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors

Trial ID MRTX1133
Sponsor ID 1133-001

A Phase 1/2 Multiple Expansion Cohort Trial of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation

Trial ID IDE161-001
Sponsor ID IDE161-001

A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors

Trial ID DK210 (EGFR)
Sponsor ID DEKA Biosciences

Dose-finding Phase 1 Trial: Evaluating Safety and Biomarkers Using DK210 (EGFR) for Inoperable Locally Advanced and/or Metastatic EGFR+ Tumors With Progressive Disease Failing Systemic Therapy

Trial ID CBP-1019
Sponsor ID CBP-1019-101

An Open-Label, Non-randomized, Multinational, Multi-center Phase I/Ⅱ Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Bi-Ligand-Drug Conjugate CBP-1019 in Patients With Advanced Solid Tumors

Trial ID BMF-219
Sponsor ID COVALENT-102

A Phase 1/1b Dose Finding Study of BMF-219, an Oral Covalent Menin Inhibitor, in Adult Patients With Unresectable, Locally Advanced, or Metastatic Non-small Cell Lung Cancer (NSCLC), Pancreatic Cancer (PDAC), and Colorectal Cancer (CRC)

Trial ID 21235
Sponsor ID Comet

A randomized, double-blind, phase III study comparing NIS793 in combination with gemcitabine and nab-paclitaxel versus placebo combined with gemcitabine and nab-paclitaxel for first line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC)

Principal Investigator
Keeran R. Sampat, MD
3 Locations
Trial ID Xbiotech PT049
Sponsor ID Xbiotech USA Inc

A Phase I/II randomized, double-blind, placebo-controlled trial (1-BETTER) examining XB2001 (anti-IL-1⍺ True Human antibody) in combination with ONIVYDE + 5-FU/LV (+folinic acid) in advanced pancreatic cancer

Principal Investigator
Keeran R. Sampat, MD
3 Locations